EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Penzel, Roland (VerfasserIn) , Sers, Christine (VerfasserIn) , Chen, Yuan (VerfasserIn) , Lehmann-Mühlenhoff, Ulrich (VerfasserIn) , Merkelbach-Bruse, Sabine (VerfasserIn) , Jung, Andreas (VerfasserIn) , Kirchner, Thomas (VerfasserIn) , Büttner, Reinhard (VerfasserIn) , Kreipe, Hans H. (VerfasserIn) , Petersen, Iver (VerfasserIn) , Dietel, Manfred (VerfasserIn) , Schirmacher, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2011
In: Virchows Archiv
Year: 2011, Jahrgang: 458, Heft: 1, Pages: 95-98
ISSN:0945-6317
Online-Zugang: Volltext
Verfasserangaben:hRoland Penzel, Christine Sers, Yuan Chen, Ulrich Lehmann-Mühlenhoff, Sabine Merkelbach-Bruse, Andreas Jung, Thomas Kirchner, Reinhard Büttner, Hans H. Kreipe, Iver Petersen, Manfred Dietel, Peter Schirmacher
Beschreibung
Zusammenfassung:EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed.
ISSN:0945-6317